{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:27:40Z","timestamp":1773664060760,"version":"3.50.1"},"reference-count":38,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Legend Biotech USA Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.1080\/14737167.2026.2634771","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:18:50Z","timestamp":1772727530000},"page":"369-378","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"first","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute","place":["Tampa, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Lu","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute","place":["Tampa, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rameet","family":"Sachdev","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific","place":["Waltham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"De Wiest","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Huo","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC","place":["Raritan, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seina","family":"Lee","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC","place":["Raritan, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"e_1_3_7_3_1","volume-title":"StatPearls","author":"Ahmed A","year":"2023","unstructured":"Ahmed A, Killeen RB. Relapsed and refractory multiple myeloma [updated 2023 Jun 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK592405\/"},{"key":"e_1_3_7_4_1","unstructured":"American Cancer Society. Key statistics about multiple myeloma [Internet]. [updated 2025 Feb 28; 2025 Apr 11]. Available from: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html"},{"key":"e_1_3_7_5_1","unstructured":"National Cancer Institute. Cancer stat facts: myeloma [Internet]. [cited 2025 Apr 18]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00804-y"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010155"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092"},{"key":"e_1_3_7_11_1","unstructured":"U.S. Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma [Internet]. 2022 [cited 2023 Oct 18]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_7_14_1","unstructured":"U.S. Food and Drug Administration. CARVYKTI\u00ae (ciltacabtagene autoleucel) suspension for intravenous infusion [Internet]. 2024 [cited 2025 Apr 28]. Available from: https:\/\/www.fda.gov\/media\/156560\/download"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760"},{"key":"e_1_3_7_16_1","unstructured":"Johnson and Johnson. Carvykti - CARTITUDE-4 (MMY3002) study. 2024. Available from: https:\/\/www.jnjmedicalconnect.com\/products\/carvykti\/medical-content\/carvykti-cartitude4-mmy3002-study#OSA_Efficacy_Resposnerate_33months"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201533"},{"key":"e_1_3_7_18_1","unstructured":"National Comprehensive Cancer Network. Multiple myeloma version 4. 2024 [cited 2024 Aug 1]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408892"},{"key":"e_1_3_7_20_1","unstructured":"CancerMPact. Treatment architecture: multiple myeloma US: oracle Life sciences. 2022 [cited 2024 Aug 1]. Available from: https:\/\/cancermpact.lsapps.oracle.com\/"},{"key":"e_1_3_7_21_1","unstructured":"Practice Management Information Corporation. Medical fees directory [Internet]. 2024 [cited 2024 Aug 1]. Available from: https:\/\/www.pmiconline.com\/fees"},{"key":"e_1_3_7_22_1","unstructured":"Centers for Medicare and Medicaid. PFS look-up tool overview [Internet]. [updated 17 April 2025; cited 2024 Aug 1]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00228-5"},{"key":"e_1_3_7_24_1","unstructured":"Merative. Micromedex\u00ae RED BOOK\u00ae. [cited 2024 Aug 1]. Available from: https:\/\/www.micromedexsolutions.com\/"},{"key":"e_1_3_7_25_1","unstructured":"Centers for Medicare and Medicaid. ASP pricing files [Internet]. [cited 2024 Aug 1]. Available from: https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files"},{"key":"e_1_3_7_26_1","unstructured":"National Comprehensive Cancer Network. Guidelines multiple myeloma v5.0. 2022."},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0080"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024995"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.04.685"},{"key":"#cr-split#-e_1_3_7_30_1.1","unstructured":"U.S. Food and Drug Administration. BREYANZI\u00ae (lisocabtagene maraleucel) suspension for intravenous infusion. 2021 [updated June 2022"},{"key":"#cr-split#-e_1_3_7_30_1.2","unstructured":"cited 2023 Oct 18]. Available from: https:\/\/www.fda.gov\/media\/145711\/download"},{"key":"e_1_3_7_31_1","unstructured":"Novartis. FDA approves Novartis kymriah\u00ae CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma [Internet]. 2022 [cited 2023 Oct 18]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma"},{"key":"e_1_3_7_32_1","unstructured":"Janssen Science. CARVYKTI\u00ae (ciltacabtagene autoleucel) Medical Information [Internet]. [cited 2023 Oct 18]. Available from: https:\/\/www.janssenscience.com\/products\/carvykti\/medical-content\/carvykti-outpatient-administration"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.04.416"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221142945"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2207742"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013239"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245746"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.242"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.543"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2634771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:45:23Z","timestamp":1773661523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2634771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,16]]}},"alternative-id":["10.1080\/14737167.2026.2634771"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2634771","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}